International Journal for Research in Applied Sciences and Biotechnology

ISSN: 2349-8889
Volume-9, Issue-2(March2022)

www.ijrasb.com

https://doi.org/10.31033/ijrasb.9.2.5

Chest CT Findings that Mimics Covid 19 Pneumonia: Review Article

Abeer Wali Ahmed[1], Mohamed Muyaser[2] and Rasha Nadeem Ahmed[3]
[1]Lecturer, Department of Surgical, Ninevah Medical Collage, IRAQ
[1]Lecturer, Department of Surgical, Ninevah Medical Collage, IRAQ
[1]Lecturer, Department of Surgical, Ninevah Medical Collage, IRAQ

[1]Corresponding Author: abeer.ahmed@uoninevah.edu.iq

ABSTRACT

Coronavirus disease 2019 (COVID-19) emerged in early December 2019 in China, as an acute lower respiratory tract infection and spread rapidly worldwide being declared a pandemic in March 2020. Chest-computed tomography (CT) has been utilized in different clinical settings of COVID-19 patients; however, COVID-19 imaging appearance is highly variable and nonspecific. Indeed, many pulmonary infections and non-infectious diseases can show similar CT findings and mimic COVID-19 pneumonia. In this review, we discuss clinical conditions that share a similar imaging appearance with COVID-19 pneumonia, to identify imaging and clinical characteristics useful in the differential diagnosi Coronavirus disease 2019 (COVID-19) emerged in early December 2019 in China, as an acute lower respiratory tract infection and spread rapidly worldwide being declared a pandemic in March 2020. Chest-computed tomography (CT) has been utilized in different clinical settings of COVID-19 patients; however, COVID-19 imaging appearance is highly variable and nonspecific. Indeed, many pulmonary infections and non-infectious diseases can show similar CT findings and mimic COVID-19 pneumonia. In this review, we discuss clinical conditions that share a similar imaging appearance with COVID-19 pneumonia, to identify imaging and clinical characteristics useful in the differential diagnosi Coronavirus disease 2019 (COVID-19) emerged in early December 2019 in China, as an acute lower respiratory tract infection and spread rapidly worldwide being declared a pandemic in March 2020. Chest-computed tomography (CT) has been utilized in different clinical settings of COVID-19 patients; however, COVID-19 imaging appearance is highly variable and nonspecific. Indeed, many pulmonary infections and non-infectious diseases can show similar CT findings and mimic COVID-19 pneumonia. In this review, we discuss clinical conditions that share a similar imaging appearance with COVID-19 pneumonia, to identify imaging and clinical characteristics useful in the differential diagnosi Coronavirus disease 2019 (COVID-19) emerged in early December 2019 in China, as an acute lower respiratory tract infection and spread rapidly worldwide being declared a pandemic in March 2020. Chest-computed tomography (CT) has been utilized in different clinical settings of COVID-19 patients; however, COVID-19 imaging appearance is highly variable and nonspecific.

Indeed, many pulmonary infections and non-infectious diseases can show similar CT findings and mimic COVID-19 pneumonia. In this review, we discuss clinical conditions that share a similar imaging appearance with COVID-19 pneumonia, to identify imaging and clinical characteristics useful in the differential diagnosi Coronavirus disease 2019 (COVID-19) emerged in early December 2019 in China, as an acute lower respiratory tract infection and spread rapidly worldwide being declared a pandemic in March 2020. Chest-computed tomography (CT) has been utilized in different clinical settings of COVID-19 patients; however, COVID-19 imaging appearance is highly variable and nonspecific. Indeed, many pulmonary infections and non-infectious diseases can show similar CT findings and mimic COVID-19 pneumonia. In this review, we discuss clinical conditions that share a similar imaging appearance with COVID-19 pneumonia, to identify imaging and clinical characteristics useful in the differential diagnosis Coronavirus disease 2019 (COVID-19) emerged in early December 2019 in China, as an acute lower respiratory tract infection and spread rapidly worldwide being declared a pandemic in March 2020. Chest-computed tomography (CT) has been utilized in different clinical settings of COVID-19 patients; however, COVID-19 imaging appearance is highly variable and nonspecific.

Indeed, many pulmonary infections and non-infectious diseases can show similar CT findings and mimic COVID-19 pneumonia. In this review, we discuss clinical conditions that share a similar imaging appearance with COVID-19 pneumonia, to identify imaging and clinical characteristics useful in the differential diagnosis Coronavirus epidemic 2019, known as (COVID-19) first appeared in China early December 2019 like an acute lower respiratory system illness as well as quickly expanded around the globe, eventually becoming a global in March 2020. COVID-19 individuals have undergone chest computed tomography (CT) in a variety of therapeutic settings; nonetheless, the look of COVID-19 scanning is very varied or vague. Several lung illnesses, such as bacterial pneumonia, A-typical bacterial pneumonias, viral pneumonia, fungal infection, and hypersensitivity pneumonia Super-infection/co-infection, might resemble COVID-19 pneumonia in CT. Inside this study, we detected or treated which have comparable visual appearances with COVID-19 pneumonia through order to obtain image and medical features that might help with diagnostic process.

Keywords- Super-infection/co-infection, COVID-19 pneumonia, CT findings.

I. INTRODUCTION

This same clinical appearance of COVID-19 is very varied and vague, with the most frequent symptoms including cough, fever, anosmia, dyspnea, dysgeusia,

ISSN: 2349-8889
Volume-9, Issue-2(March2022)

www.ijrasb.com https://doi.org/10.31033/ijrasb.9.2.5

lethargy, or muscular pains. Many people have a serious bacterial meningitis that leads to pulmonary collapse or mortality, whereas others recuperate entirely. Furthermore, inside a considerable majority of patients, COVID-19 disease is asymptomatic. This reverse-transcription polymerase chain reaction (RTPCR), that identifies viral nucleotide in nasopharyngeal and nasopharynx swab collections, bronchoalveolar lavage, or tracheal biopsy, is indeed the clinical screening approach for COVID-19 infections. Due to incorrect collection, sample kind, or viremia just at time of examination, RT-PCR specificity is expected to really be around 60 to 71 %. Specimen collection or disposal, kit shortages, as well as process time are all constraints of RT-PCR. CT scans of the breast are a common but quick way to diagnose pulmonary pathologies, both viral or non-infectious illnesses of the lungs[1].

According to a few research, chest-CT can detect respiratory irregularities through COVID-19 patients to such a untrue RT-PCR test inside the initial phases of illness as well as identify factors suitable with COVID-19 pneumonia in asymptomatic patients people treated CT investigation for other purposes inside a family setting. During the COVID-19 epidemic, chest-CT was frequently employed since it is a quick and easy-to-use method in most hospitals. CT shows a high specificity to 94–97% in identifying initial indications of COVID-19 pneumonia, illness development, sequelae, and alternate diagnosis like heart problems or arterial edema. Unfortunately, since numerous lung illnesses may resemble COVID-19 pneumonia CT look, the sensitivity of CT is limited (around 37%). In fact, several radiography professional associations advise against using CT like a main diagnostic tool for COVID-19 pneumonia[2-3].

The Fleischner Society Multinational Consensus Statement, for instance, aims to standardise the parameters of using or interpreting CT inside the COVID-19 pandemic by categorizing sufferers based on their susceptibility or degree of symptoms. CT is not indicated as a screening procedure for COVID-19 infection in asymptomatic individuals or in persons with moderate symptoms consistent with COVID-19 disease, according to the Multinational Consensus Statement, unless there are hazard variables for advancement. sick patients with ranging from mild to serious symptomatology, irrespective of the RTPCR consequence, as well as patients with declared COVID-19 infectious disease who are experiencing rapidly deteriorating respiratory issues, should undergo CT. Many hospitals now use 64-, 256-, and 128-slice multi - detector row CT scanners to do pulmonary CT. Photos are obtained using typical tube voltage or current parameters (120 kV, 200 mAs, fluctuating based on the patient's BMI, 16 0.75 divider, with pitched = 0.938) with a detection spectrum spanning the region from its pulmonary apices toward the abdomen, with an imaging orientation of coronal plane monitoring. Patients are usually examined while lying down in a posterior posture and holding a deep inhalation[4].

This supine posture, on either hand, may help distinguish between anterior or posterior hepatocellular anomalies as well as reliant pulmonary atelectasis. Expiratory scans may be required to separate air-trapping from hypo-vascular patchwork degradation; however, they are not frequently done since they are extremely taxing for persons with severe illness, like COVID-19 pneumonia. Pictures are rebuilt with a computed tomography of 1.00 or 1.25 mm as shot at windows setting adequate for examining lungs tissue (600 to 700 HU; window breadth, 1200–1500 HU) as well as the pulmonary trunk (window level, 20–40 HU; window width, 400 HU).

Ground-glass opacity (GGO) is a crucial image result for COVID-19 pneumonia, characterized like a region of foggy enhanced pulmonary attenuate that does not obscure bronchial or arterial features. It indicates complete occlusion of alveolar air passages that could be caused by a variety of factors, therefore its clinical usefulness in isolation is limited[5-6]. GGO can be classified by arterial (namely the, elevated vascular blood volume or stress, like in cardiac failure) and non-vascular (namely, full filling or collapsing of alveoli, including intervening thickness owing to liquid, cells, or fibrosis), or perhaps a mix of factors. Asymmetric, multicenter, spotty GGO with or without concomitant regions of accumulation, often with a basal peripheral pattern, is the most common CT result in COVID-19 pneumonia. Superimposed just on GGO, ventral or interstitium septum hypertrophy may sometimes be detected, culminating in a "crazy-paving pattern". Pure accumulation is unusual that only occurs in adults above the age of 50, especially progressing instances, or in those with more serious infection CT could reveal the "reverse halo sign" (an anomalous occlusion with such a dense ancillary circle of centralization as well as a central area of GGO) in patients who develop an organising pneumonia (OP) sequence, that has been seen in 32.1% of people with mild illness as well as 13% of sick people with extra serious illness. COVID-19 infections are linked to pulmonary infarctions, pulmonary embolism, or capillary thrombosis, all of which may be seen on CT as periphery opacification[7].

CT can also assist distinguish between various respiratory illnesses, acute heart failure, or arterial embolism whenever conducted with contrasting media. CT symptoms of COVID-19 pneumonia might differ tremendously based on the stage or intensity of the illness, with chest-CT being unremarkable in 10.6% of symptomatic patients. One purpose of this paper is to offer a collection of pathological illnesses which may been mistaken for COVID-19 pneumonia depending on CT appearances similarity, as well as to discuss diagnostic aspects or clinical factors which can aid in diagnostic process.

ISSN: 2349-8889
Volume-9, Issue-2(March2022)

www.ijrasb.com https://doi.org/10.31033/ijrasb.9.2.5

1.1 Pulmonary infection

1.1.1 Bacterial pneumonia

During medical care, pulmonary diseases are widespread, but bacterial meningitis is among the most likely reasons. Depending upon the medical context, this is defined into community acquired pneumonia (CAP), respiratory infections, and nosocomial pneumonia (NP). CAP is induced by Streptococcus pneumoniae and Mycoplasma pneumoniae; NP is triggered through Staphylococcus aureus or Gram-negative (Enterobacteriae as well as E. coli), whilst also ambition meningitis is exacerbated by Gram-negative cocci discovered inside the oropharynx. Temperature, shivers, coughing, with chest pain are typical medical signs; however, in immune-compromised individuals, signs may be reduced and nonexistent.

Whenever pneumonia is indicated, radiological assessment is done to confirm this diagnosis, with both a chest X-ray (CXR) becoming the most often utilised technique[8]. CT is highly accurate, and it's only used in instances where the diagnosis isn't apparent or even when problems are anticipated. CT imaging of CAP indicate airspace accumulation, as well as GGO, centrilobular cysts, or airway clot formation, with or without pericardial fluid. Round or multi-lobar influenza are less common appearances. The initial one is characterised by a focused, round-shaped consolidation during imaging, which is commonly found in kids.

If a rapidly expanding lung nodule/mass vanishes following antibiotic treatment, round pneumonia must be considered. Non-focal types for CAP, such as multi-lobar and unilateral pneumonia, are frequently found in patients with a chronic lung illness that causes parenchymal deformation. Breathing of oropharyngeal and stomach fluids into the lower respiratory tract causes pulmonary edema. Bilateral or peri-hilar interstitial restructurings encompassing inferior lobes, particularly inside the right lung, are often seen on imaging[9-10].

Acute pneumonia developing 48 hours after admittance or 48 hours following hospital release is regarded like a consequence of hospitalised patients. Bilateral, widespread, or numerous foci of accumulation encompassing more than single lobe are mri observations that are commonly linked with pericardial effusion. Complications can occur in every kind of pneumonia, although they are more common in CAP or NP, particularly in immuno compromised patients, and thus are generally diagnosed by CT. Lung cavitation supports a bacterial aetiology, with S. aureus or anaerobes being the most common pathogens in immuno competent patients with Aspergillus being the most common pathogen in immuno compromised patients. Pleural fluid overload are common with simple CAP and thus are reactive in nature, healing following antibiotic treatment. Conversely, 5–10% of these can worsen or proceed to empyema.

1.2 A-typical bacterial pneumonias

SARS-CoV-2 (severe severe pulmonary syndromes coronavirus) was discovered for the very initial time at Wuhan, China, just at end of 2019 it is the cause of Coronavirus illness, an infectious lung illness (COVID-19). COVID-19 has spread fast around the globe, with 209.87 million verified illnesses with 4400 thousand fatalities end of August 20, 2021. Since about Aug 20, 2021, India has 32.35 million known cases with 433 thousand fatalities. COVID-19 has a wide range of therapeutic manifestations, from microbial infections to deadly illness characterised by acute respiratory distress syndrome (ARDS) or multi - organ collapse.

Bacterial co-infections linked with COVID-19 have been documented regularly, although its prevalence is minimal when contrasted to prior pandemic influenza. According to Lansbury et al., 7% of hospitalised COVID-19 patients developed microbial co-infections, including a greater proportion of 14% in intensive care unit (ICU) participants[11]. Several investigations have shown SARS-CoV-2 co-infection with unusual microorganisms like Mycoplasma pneumoniae, Legionella pneumophila, or Chlamydia pneumoniae. It's hard to tell the difference between SARS-CoV-2 or germs that cause atypical pneumonia since their clinical manifestations or imaging characteristics are so similar. Aside from that, it's unknown if co-infection by atypical bacteria might result in COVID-19 patients getting inferior diagnostic evidence. Researchers conducted detailed research to investigate the incidence of atypical bacteria co-infection in COVID-19 patients transferred to an Indian tertiary hospital. They also go through the sociodemographic characteristics for similar co-infections, as well as laboratory parameters, sequelae, or patient results.

This extreme acute pulmonary sickness coronavirus (SARS-CoV-2) epidemic, that produces coronavirus disease 2019 (COVID-19), represents this decade's worst pandemic, involving 16 million people infected with 650,000 fatalities thus far. Also when individuals have comparable risk factors, one of the big puzzles inside this epidemic is whether certain individuals get gravely sick some have very moderate symptoms. Secondary infectious diseases are more common in COVID-19 patients, as they are linked to poorer prognosis. Secondary bacterial infections were shown to be strongly linked with result harshness in a multinational research including 476 COVID-19 participants[12-13]. Individuals were put in three categories in the research (moderately ill, severely ill, as well as critically ill). As comparison to patients inside the moderately unwell or seriously ill categories (3.9 % or 8.3 %, correspondingly), critically ill people had a greatest prevalence with microbial co - infection (34.5 %). Most alarming, this greater occurrence of co-infections in crucial individuals occurred despite the fact that a vast bulk of them (92.9%) got antibiotic therapy, comparing to 59.4% or 83.3 % inside the moderately

sick or seriously ill groups, respectively[14]. For addition, microbial co-infections developed for 15% of 191 COVID-19 patients, included 50% of non survivors, despite the fact that 95% of patient populations received medicines, according to Zhou as well as colleagues. Much more concerning, 27 of the 28 COVID-19 patients who had co-infections died.

Several co-morbidities were linked with death in each investigation, making it hard to pinpoint the specific effect of co-infections. Real-time Amplification is utilised inside another subsequent investigation to determine particular bacteria that cause COVID-19 co-infections. Researchers discovered that 243 (94.2%) of individuals are contaminated including atleast one of 39 diseases. Pathogenic bacteria were more common (91.8%) than viral (31.5%) or antifungal (23.3%) illnesses[15]. Despite the lack of a link among co-infection frequencies with result harshness or death, the authors identified intriguing co-infection trends in several therapeutic categories (asymptomatic, moderately, significantly, and gravely sick). Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus, Aspergillus, Klebsiella pneumoniae, Haemophilus influenzae, as well as the Epstein-Barr (EB) viral infection, for example, were found in all 4 treatment populations, whereas Pseudomonas aeruginosa, sentient attenuated virus, sentient rotavirus, as well as herpes viruses were found only in outpatient clinic signs Co-infections with pandemic A, influenza B, and coronavirus were not prevalent in these COVID-19 individuals, despite its fact that specimens were taken throughout influenza season[16]. Overall, these preliminary findings imply that the particular contaminate food microorganisms can impair illness outcome, indicating that more research is needed. Although it is uncertain if co-infections impact COVID-19 health results decisively, historical evidence from epidemics or flu virus suggests that microbial co-infections may exacerbate viral illnesses.

Approximately to 30% of patients were identified having secondary infections during initial SARS-CoV epidemic in 2003, but co-infection was related significantly with illness severity. Microbial co-infections are also prevalent in 2 % to 65 % of patients over typical flu epidemics that are linked to disease or death. Furthermore, throughout the influenza season inside the United States from 2004 - 2007, bacteria co-infection frequencies in kids surged dramatically from 6% (2004 - 2005) to 15% (2005 - 2006) or 34% (2006 to 2007). The rising prevalence of microbial co-infections during influenza period highlights the critical necessity to learn everything about this phenomena, particularly as it pertains to COVID-19. During our struggle to rescue COVID-19 sufferers from microbial co-infections, we're administering additional antibiotics, so it’s crucial to think on how this can influence the worldwide frequency of antibacterial drugs bugs[17]. Despite widespread infection prevention and regulate, prices of methicillinresistant S. aureus acquirement increased significantly throughout this same “1st Incident, from 3.53 % pre-SARS to 25.30 % as during Sars epidemic, as per assessments of isolated strains gathered from hospital intensive care unit (ICU) at Prince of Wales Hospital (Hong Kong) from 12 March to 31 May 2003. Additional infections were discovered in posthumous lungs tissues from Hong Kong or Singapore individuals, including Klebsiella spp., S. aureus, P. aeruginosa, or S. pneumonia, these are most recognised for their significant medication tolerance”. Although it is unclear if the COVID-19 epidemic will lead inside a rise of antibacterial drugs germs, as antibiotic usage does not necessarily result in an upsurge in drug-resistant organisms, incidence of antibacterial drugs infectious diseases must be monitored. Such findings from the present COVID-19 pandemic, preceding pandemics, or seasonal influenza pose critical problems that must be answered. Initially, do the SARS-CoV-2 viruses or some co-infecting microorganisms have synergistic encounters? Secondly, does co-infection with antibacterial drugs germs have an impact on the severity of disease?

Furthermore, several of the bacteria found in COVID-19 sufferers may be sensitive to antibiotics, reducing the effectiveness of therapies given to patients[18]. However, the particular co-infecting viruses discovered during first two investigations, wherein co-infections were linked with poorer results were not specified, because no research have examined frequencies of co-infection by antibacterial drugs organisms to date. As a result, determining whether particular species of bacteria and antibiotic-resistant populations connect with result harshness and fatality is difficult based on the existing information. Moreover, the existence of antibiotic-resistant germs might explain why severely sick patients have such significant incidence of microbial co-infections despite getting substantial antimicrobial treatment. Lastly, the fight against COVID-19 has the potential will exacerbate our existing severe problem with antibiotic-resistant organisms. Multidrug-resistant microorganisms are becoming very common, although their ability can remove those was dwindling[19]. This makes humans increasingly susceptible to infectious illnesses, as well as weakening us throughout viral pandemics. Researchers definitely have to explore the consequences of bacteria co-infections in viral infections as identify novel antimicrobial agents to destroy multi drug resistance organisms to address the significant problem.

1.3 Viral Pneumonia

Acute respiratory illnesses are mostly caused by pathogens. Infections may induce bacterial meningitis based on the patient's age or immunological condition. Clinical signs are non-specific or vary depending on immunological condition (severity is higher in immuno compromised individuals), aging, or viral frequency. Because these intersect or are associated with various

ISSN: 2349-8889
Volume-9, Issue-2(March2022)

www.ijrasb.com https://doi.org/10.31033/ijrasb.9.2.5

non-viral lung illnesses, radiological findings are varied or non-specific. CT results indicate virus - induced pathophysiology: pathogens from the similar group with comparable pathogenesis have comparable CT appearances.

For many immuno competent people, adenovirus causes a moderate upper respiratory illness. It can, though, induce severe bronchiolitis, that can progress to bronchiolitis. Bilateral, multifocal GGO with spotty merger, typically with such a vertebral pattern, indicative of broncho pneumonia, and accompanied with tree-in-bud-opacities are seen on CT in severe viral pneumonia. Owing to modest airway blockage or lower pulmonary resistance, exhalation recordings can show regions of water entrapment, that are observed in regions and diminished attenuate of lungs tissue after expiration[20-21]. Chronic bronchiolitis is frequently the cause. In immuno compromised individuals, like HIV patients, people on long-term corticosteroid medication, and renal transplant recipients, cytomegalovirus (CMV) infection is increasingly common, particularly in the initial stages (30–100 days) following transplants. Individuals that are immune-competent are frequently asymptomatic.

CT shows unilateral or asymmetrical GGO in CMV pneumonia, as well as randomly dispersed, ill delineated lung lesions with air-space accumulation. Sinus hypertrophy between the lobes has been reported.

Flu viruses are a diverse collection of infectious organisms (influenza viruses A, B, C, or D) that cause upper respiratory illnesses inside the form of annual epidemics or pandemics. Infections are normally moderate or self-limiting, although pneumonia, which is produced primarily by the Influenza A viruses, can develop in immuno compromised individuals, kids, as well as the older. CT may indicate contralateral GGO which is localised and widespread, with merger that are collinear (Fig. 3). Flu infection is associated with bronchiectasis or tiny central vein lesions, which were uncommon in COVID-19. Pleural effusion or cavitation may occur with viral infection.

Mostly during winters, human meta pneumovirus (HMPV) is responsible for around 4% of CAP cases. Immuno competent people recuperate without complications, however immuno compromised individuals can acquire an existence pneumonia. HMPV infection occurs to mucosal trapping or alveolar injury, culminating inside a CT signal of branched central vein nodules with GGO. This family of microorganisms known as humans corona viruses causes upper or lower pulmonary system illnesses, as well as acute pulmonary crisis syndrome[22]. The category includes the SARS or MERS infections. SARS pneumonia MRI characteristics were similar to those seen in other CAP: space restructurings are a predominant prevalent observation, and strong focus patterns being more frequent than multicenter patterns. This participation of a tissue is mostly within the inferior portion, with a widespread dispersion.

MERS pneumonia is a serious illness that may cause respiratory distress faster than SARS pneumonia. Multifocal spotty nodule restructurings with widespread GGO covering the base or subpleural areas both of lungs are often seen in CT with MERS pneumonia. Imaging CT characteristics of COVID-19 pneumonia may be very similar to those of similar infectious pneumonias[23]. Certain results, although, have been observed to be more diagnostic of COVID-19 pneumonia than other etiologies, which might aid inside the differentiation of this organism.

With COVID-19 pneumonia, clean GGO or mixed GGO with accumulation patterns are the greatest prevalent, whereas clean mergers are uncommon and much more frequent in similar viral pneumonias, like influenza pneumonia. COVID-19 contamination results in unilateral massive hepatocellular lesions (> 5–10 cm), which are commonly spherical in form, include many lungs, and have a distinct periphery dissemination. Additional typical observations include interlobular septum enlargement, bronchial clot formation, longitudinal aperture settings, or capillary hypertrophy. When opposed with similar virus infection, such as influenza, the "crazy paving" feature is more common in COVID-19 pneumonia.

Tree-in-bud opacification, numerous nodules, bronchiectasis, increased air restructurings, pericardial effusion, or lymphadenopathy augmentation, on either hand, are most likely to be caused by other agents. Lung mergers are more prevalent in non-HIV individuals with quickly progressing infections, demonstrating parenchymal harm inflicted by the human immunological reaction[24-25]. Pulmonary air-containing cysts, which may vary in size or form, are seen in one-third of individuals or are more common in HIV individuals. Cysts are linked to an increased risk of pneumothorax, although they may heal with proper infections therapy. Solitary or numerous lesions varying in size from a several millimetres to one centimetre can form because a result of granulomatous inflammation. Following healing, structural deformation or persistent scarring can remain.

II. FUNGAL PNEUMONIA

GGOs, nodular allow greater, a tree-in-bud pattern, or cavitating restructurings are also possible radiological abnormalities in fungal pneumonia. With angioinvasive aspergillosis, another CT halo signal have been identified wherein all encircling GGOs signify bleeding. Through contrast, for candidiasis, cryptococcosis, or coccidioidomycosis, a CT halo signal may be found. Mucormycosis, intrusive respiratory[26]. Despite the fact that several CT results of fungus influenza are similar to that of COVID-19 pneumonia, clinical existence of central vein granular

opacification, cavities, chest wall encroachment, empyema, or lymphadenitis strongly suggests a fungal infection.

III. OTHER INFECTIOUS DISEASES

a. COVID-19 pneumonia might be mistaken for it. Axial CT scan of the right inferior lobe reveals an accumulation with round shape. Inside this pulmonary panel, Hemophilus infuenza were discovered.
b. This right upper lobe has a comparable circular condensation. This individual confirmed positive for COVID-19 pneumonia using RT-PCR. Additional factors were ruled out by the pulmonary panel.
c. Inside the person having Haemophilus influenzae pneumoniae infection, an axial CT picture reveals GGOs with concomitant merger.
d. On an axial CT picture of a patient having COVID-19 pneumonia, bilateral GGOs with merger are shown, comparable to (c).
e. Through an immuno suppressed individual having PJP disease, an axial CT picture showed GGOs across contralateral higher lobes.
f. GGOs in both higher lobes inside a person with COVID-19 pneumonia. GGOs on emphysematous parenchyma can cause PJP to malfunction. PJP has a pleural effusion saving advantage.
g. In a person with influenza A pneumonia, an axial CT picture reveals unilateral collaborative and interactive opacification inside the inferior portion.
h. Bilateral opacities inside the inferior portion are seen through a person with COVID-19 pneumonia. Duzgun and colleagues. In contrast, for candidiasis, crypto coccosis, or coccidioido mycosis, a CT halo signal can be found. Mucormycosis, paracoccidioido mycosis, histoplasmosis, invasive pulmonary as per gillosis, or crypto coccosis have all been linked to the reversed halo signal.

While several CT findings of fungal pneumonia or COVID-19 pneumonia are similar, the appearance of central vein granular opacities, cavitation, chest wall encroachment, thoracic efusion, or lymphadenitis favours the identification of a fungal infection.

IV. SUPER-INFECTION/CO-INFECTION

According to a recent systematic review, microbial or viral co-infection frequencies among COVID-19 hospitalised patients were 7% or 3%, correspondingly. Furthermore, individuals in intensive care units (ICUs) had a greater risk of microbial co-infection (14 %). While COVID-19 pneumonia might resemble other respiratory problems, unusual findings including pleural efusion, lobar consolidation, lymph adenopathy, or centrilobular nodular opacities might raise suspicions of super-infection and co-infection in COVID-19 pneumonia sufferers. Reasons that are not pathogenic summarises the clinical relationship between COVID-19 pneumonia CT findings as well as several non-infectious differential illnesses.

V. HPERSENSITIVITY PNEUMONIA

HP is an inflammation and fibrotic illness impacting the lung parenchyma or small bronchi that is caused through an immunological response among vulnerable people following recurrent contact with 1 or more triggering stimuli. Intermittent, acute, or persistent classifications of HP have being discarded for a considerable time[27-28]. The most recent suggested categorization divides HP into fibrotic (namely, existence of fibro with or without inflammatory) or non-fibrotic (namely, solely inflamed) categories depending upon the amount of radiographic or histological stiffness. This novel method is simpler to use that more accurately represents the virus's medical history, with hepato cellular fibrosis serving as primary prognostic marker[29]. This non-fibrotic HP, which key results include bilateral or symmetric spotty ground-glass regions with restructurings, along with mosaics patterned retardation, is the radiological characteristic that could resemble COVID-19 infection.

Non-fibrotic HP, on either hand, has more dispersed hepato cellular modifications, with no clear cranial-caudal or axial slope; dispersion and bi - lateral sick central vein mottling (chosen to reflect comparatively tiny respiratory participation) are common, just like is significant air entrapment, that could indeed be reliably recognised only by respiration mergers (Fig. 1). These traits are uncommon in COVID-19 so can be used to distinguish two organisms, along with the past underlying antigen sensitization.



Figure 1: (a–b Axial supine (a) and prone (b) HRCT images of a patient with non-fibrotic hypersensitivity pneumonitis showing small bilateral ground-glass centrilobular nodules (a) and bilateral patchy ground-glass opacities with lobular air-trapping (arrows in b) resulting in a mosaic pattern attenuation

ISSN: 2349-8889
Volume-9, Issue-2(March2022)

www.ijrasb.com https://doi.org/10.31033/ijrasb.9.2.5

VI. ACUTE FIBRINOUS AND ORGANIZING (AFOP)

Acute fibrinous or organising pneumonia (AFOP) is an uncommon lung illness histology type. Organizing Pneumonia (OP) might be more common than previously thought in COVID-19 lung damage sufferers. This case article analyzes the symptoms or progression of AFOP inside a COVID-19 individual. Description of the situation A 49-year-old man is identified with COVID-19 after presenting severe fever, breathlessness dyspnea, as well as a drier coughing while taking Venetoclax or Obinutuzumab for Diabetes as well as Chronic Lymphocytic Lymphoma[30]. His CT scan revealed widespread peripheral ground glass opacification that were uneven or heterogeneous, as well as mediastinal lymph adenopathy (Image A). The plasma aspergillus galactomannan score is 4.37, so chemical substance has been prescribed. He stayed feverish, though, and developed an endobronchial cryobiopsy. Intercellular T-cell lymphocytic inflammation infiltration with fibrinous or organised pneumonia was found on his biopsy results. Cell proliferation bronchiolitis or severe arterial bleeding were present, although there were no signs of vasculitis and capillaritis[31-32]. There was no sign of cancer and microorganisms. He was begun on everyday methylprednisolone as immediately recovered; but, while the corticosteroid tapering progressed, his temperature reappeared as his oxygen needs grew dramatically. His chest CT scan revealed a significant rise in unilateral spotty regions of accumulation, as well as ground glass transparency with intralobular septum thickness ("crazy paving").

This elaborate though unfavourable progress up was contagious. He needed intrusive artificial breathing at this point, following that he was given pulses dosage corticosteroids for 3 days and then high dosage upkeep[33]. He recovered and was taken off the ventilator. Unfortunately, he needed high-flow supplementary oxygen but couldn't be eased from off 100 % portion of oxygen supply, thus Ruxolitinib was introduced. Tragically, his hypoxemia persisted, that he had a rapid circulatory arrest, that resulted in his death. That person passed away 40 days after becoming admitted.

6.1 Acute eosinnophilic pneumonia (AEP)

Researchers present a case of acute eosinophilic pneumonia (AEP) infectious illness caused with the coronavirus disease 2019 (COVID19). That example highlights the need of taking AEP problems into account while dealing COVID19 communicable disease[34-35]. They describe a case of acute eosinophilic pneumonia (AEP) acute bacterial with the coronavirus disease 2019 (COVID19). That example highlights the need of taking AEP problems into considerations while handling COVID19 infected patients.

The diagnostic criteria for AEP have yet to be agreed upon. Allen and associates provided comprehensive eight criteria for a diagnosis in their original publication in 1989,

1) a frenzied affliction lasting just under 7 days,
2) extreme hyponatremia (characterized as Partial pressure of oxygen, 60 mm Hg on conditioned space),
3) dissipate cardiovascular inflammatory cells on computed tomography,
4) respiratory system eosinophilia (.25 % eosinophils on BAL variance cell count or eosinophilic pneumonitis at respiratory system biopsy),
5) infectious disease exception
6) Elimination of asthmatic or even other allergic rhinitis illnesses,
7) quickly respond to corticosteroids treatment,
8) Remission of respiratory eosinophilia without any lengthy complications. Numerous revisions to the early diagnostic criterion been proposed throughout the centuries. Although research showed the atopic dermatitis and asthmatic might contribute towards Academic session, a history of allergy as well as allergic diseases were never deemed an exclusionary criterion[36]. Although many participants achieved spontaneously recovery from AEP, Philit with associates
9) Advocated that the length of complaints being raised to just under or comparable to one months,
10) The responsiveness to corticosteroids treatment not be any times during the course a clinical definition
11) Additionally, moderate AEP instances also being recorded which do not manifest with regression is a regression pulmonary disease, indicating that significant hyponatremia should be omitted from of the AEP clinical guidelines.

For diagnosis "definite" AEP, updated Philit criterion are currently used:

1) Ventilatory penetrated on mammography or scintigraphy (CT),
2) Bronchial eosinophilia as evidenced by even more of about 25% eosinophils in Biological fluids (can be supplemented by varying degrees steadily increasing proportions of immune cells and macrophages) or epithelioid pneumonitis on respiratory colonoscopy (bronchoscopy rather than surgical), as well as.
3) Non attendance of those other particular respiratory epithelioid illnesses,

AEP is an eosinophilic medical condition which manifests itself as a sudden onset of breathlessness in otherwise people with health problems. Epithelioid infiltrate inside the alveoli as well as intervening regions was indeed a hallmark histologic finding of AEP. The exact cause of eosinophil excess production and storage is unclear, while factors (interleukin might play a significant factor).

The updated Philit criterion may be used to identify AEP:

(1) severe viral disease lasting less than one months;
(2) characteristic radiographic findings;

ISSN: 2349-8889
Volume-9, Issue-2(March2022)

www.ijrasb.com https://doi.org/10.31033/ijrasb.9.2.5

(3) respiratory eosinophilia by BAL fluids with much greater then 25%age inflammatory cells (increasing %ages of lymphocyte and neutrophil) or eosinophilic infection on lungs biopsies,

(4) lack of all other specified respiratory epithelioid illnesses. Patchy or widespread respiratory aperture settings with interstitial septum thickness and moderate to severe pericardial effusion have been seen on radiography.

(5) A pulmonary examination is seldom necessary. this uses earliest phase when this illness, people experiencing AEP might have neutrophils and macrophages pathological changes lacking eosinophilia in their peripheral circulation[37-38]. Its eosinophil level is circulation plasma rises in most instances throughout the next several days.

(6) After eliminating out an inflammatory a etiology of respiratory eosinophilia, associated with side effects are used to treat AEP. AEP may develop on its own in certain situations.

The radiology features, the lack of a concomitant illness, and also the elevated eosinophil number in the biological fluids all led to the diagnoses of AEP for this patient. Researchers think that now the mRNA-based COVID-19 vaccination produced the eosinophilic reactivity, similar to other viral diseases and medications, due to the fast or quick development of clinical conditions within moments of the second dosage of the immunization.

AEP had been documented in previous studies after vaccinations, such as infectious diseases vaccination and the 23-valent pneumoniae polysaccharides vaccines. AEP was described inside the incident article produced shortly after COVID-19 inoculation with both the influenza immunization AZD1222. COVID-19 mRNA inoculation has been linked to seven inflammatory medical disorders. We provide that the very first instance of AEP after mRNA COVID-19 immunization, which was verified on BAL. There remains yet no convincing proof of a direct relationship between this illness as well as the mRNA-based COVID-19 vaccination, and more research was needed to verify causality.

6.2 CT patterns and differential criteria for acute eosinophilic pneumonia and COVID-19 pneumonia

For instances of sudden eosinophilic pneumonia with coronavirus illness pneumonia, lab results, scintigraphy semiotics, the clinically currents have been investigated. Divergent symptoms, illness trajectories, or research evaluations had all noted. Whenever individuals with coronavirus illness lung develop return with worsening symptoms, acute eosinophilic pneumonia could be anticipated; immediate glucocorticoid treatment reduces future problems. The coronavirus disease 2019 (COVID-19) epidemic started in Wuhan, China, around semi-2019, and spread quickly so over globe, resulting in such a global pandemic[39]. 1-4 COVID-19 pneumonia, in instance, is indeed the human disease most common symptom, which will be commonly defined as unilateral inflammatory sickness that was resistant to routine therapy, with just an elevated higher danger collapse and the establishment to acute respiratory distress syndrome (ARDS). Acute eosinophilic pneumonia (AEP), on either hand, manifests as a pulmonary infection that arises within days or even weeks that may proceed to ARDS, with the possibility of mortality. It may also be idiopathic or caused by inhaled harmful chemicals, medicines, or diseases. With light of the current pandemic, identifying AEP became much greater complicated, since the above medical presentation may mimic COVID-19 pneumonia[40]. As this result, extensive testing and associated with adolescent were essential for just a proper differential diagnosis.

A Computed tomography (CT)is also useful for narrowing it down the diagnostic evaluation and preventing misunderstanding. Individuals in certain situations bounce back quickly just few months of starting non-steroidal medication. Presently, reverse-transcription polymerase chain reaction (RT-PCR) seems to be the conventional diagnosis for COVID-19, with the responsiveness of 60–71 %, which again seems to be likely due to measurement mistakes, samples category, and infectivity at the time of testing.

Furthermore, even now in COVID-19 individuals having falsified RT-PCR inside the initial levels of the diseases, chest computed tomography (CCT) indicates respiratory irregularities[41]. Additionally, inside that situation epidemic population dissemination, CCT may uncover features compatible to COVID-19 influenza in symptomatic individuals receiving CCT for those other circumstances. Early symptoms of COVID-19 pneumonia, tumor growth, comorbidities, and various options diagnostic, such as heart problems and pneumothorax, could all be detected with CCT, which has a very a responsiveness of estimated 94%–97% in order to detect warning indications of COVID-19 pneumonia, tumor growth, comorbidities, or plausible option diagnosis as well as treatment, such as heart problems or pulmonary hypertension. Nevertheless, since several lung illnesses may resemble typical CCT results of COVID-19 pneumonia, this had a poor sensitivity of around 37%. Two AEP or COVID-19 medical examples were provided, along with an evaluation of associated laboratory results, CCT discourse analysis, and therapeutic current flow[42]. Symptom trends, literature studies, and distinctive indications of both the two illnesses, encompassing already explored factors or therapeutic techniques, had been noted throughout medication**.**

6.3 Acute exacerbation of intersitial lung disease (AE-ILDs)

ILDs have been more widely identified and managed in recent times within medical doctors around the nation. Although the actual prevalence of ILDs

remains unknown, their relevance as a health risk for COVID-19 had yet to be established. Throughout COVID-19, overall amount of fresh diagnosis or severe relapses was thought to be rather modest[43]. The current study's questions focus on discharges due to non-COVID severe illness of ILDs (AE ILDs) and associated outcomes previous before and during the COVID-19 timeframe.

Rapid acceleration of idiopathic pulmonary fibrosis (AE-IPF) was described as a rapid, clinically meaningful worsening that occurs in much less than one month and had no evident medical reason such as fluid resuscitation, left heart problems, or collapsed lung. Destruction to the alveoli is the most common pathophysiological hallmark of AE-IPF, and shows up on high-resolution computed tomography as widespread, unilateral ground-glass process has been time consuming and histologically as multiorgan destruction[44]. Apart from respiratory problems, a growing body of literature concentrates on acute exacerbations of interstitial lung disease (AE-ILD).

Destruction to the alveoli is the most pathophysiologic hallmark of AE-IPF, that shows up with elevated computerized neuroimaging with widespread, symmetrical ground-glass method has been efficient or histologically as multiorgan destruction. Apart from respiratory problems, a great deal of work concentrates upon acute exacerbations of interstitial lung disease (AE-ILD). AE-ILD is thought to impact all individuals with interstitial lung disease (ILD) due to a similar 6athogenesis, but it seems to be more common in those with an accompanying typical interstitial pneumonia characteristic[45-46]. Although the cause of AE-ILD is unknown, there are several major risk factors and causes, including infections, mechanical vibration, and micro aspiration.

AE-ILD seems to have a grim outcome overall generally and is linked to a significant death rate during 6 - 12 months. Given the absence of scientific proof information, AE-ILD is commonly managed during medical care with elevated glucocorticoid treatment and antibiotic. This paper seeks to offer a concise overview of the clinical manifestations, diagnostics, treatment, and outcome of AE-ILD, as well as an overview on recent discoveries inside the area.

Interstitial lung disease (ILD) is a diverse collection of diseases that are characterized by dyspnea and lung infiltration on both sides. Though certain instances were idiopathic (namely, idiopathic pulmonary fibrosis), everyone else seems to be linked to disease states (example given., immunological diseases), environmental triggers (instance , asbestosis, upper respiratory infections), or stimulant.

1). Inflammatory and an insufficient buildup of collagenous components inside the interstitial fluid of the lung cause ILD.

2). Prodromal symptoms with lung damage and other kinds of ILDs had being reported as rapidly progressing, culminating in increasing discomfort, greater oxygen supplemental needs, and respiratory distress.

3). Exacerbation of ILD had being linked with operation, inhalation in stomach lining, infections, as well as various causes. Although virulence had been suggested as a primary reason of ILD or aggravation, the infections responsible as well as the processes activated when in a flare - ups are yet unknown.

4). The possible effect of the COVID-19 epidemic on ILD has recently sparked worry, owing towards its proclivity for causing serious lung harm in the elderly or those without pre-existing respiratory illness[47-48]. The new coronavirus SARS-CoV-2 causes COVID-19.

5). They discuss the clinical case with Rheumatoid Arthritis (RA)-related ILD (RA-ILD) who was previously admitted to hospital because to COVID-19. They begin by outlining the issue or discussing the research, following by a consideration of unanswered questions which need to be investigated extensively.

ILDs (interstitial lung diseases) were a diverse category of illnesses. Despite the difference in clinical manifestations, illness development, and mortality, inflammatory reaction degradation of the pulmonary parenchyma was a common hallmark among the ILDs. Acute exacerbations of interstitial lung disease (AE-ILD) may occur at any time during the diagnostic workup of ILD and are linked associated considerable morbidity and mortality. AE-ILD had been first characterized in idiopathic pulmonary fibrosis (IPF), or an acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is defined as just a severe medical rapid deterioration of shortness breath that evolves in far typically lower just one fortnight even an alternate solution a etiology, paying particular attention the authoritative U.s Thoracic Societal structure Pulmonary function Societal structure Breathing Societal structure United states.

6. Throughout terms of pathophysiology, AE-ILD is similar to acute lung injury (ALI), that usually often manifests immune histochemistry with diffuse alveolar damage (DAD)

7.DAD, on the other hand, has been detected in individuals having connective tissue-related ILD (CTD-ILD), idiopathic fibrotic non-specific interstitial pneumonia (NSIP), and recurrent hypersensitivity pneumonitis (HP) in postmortem investigations

8. AE-ILD and ALI share additional clinical signs than only the histological DAD, including a greater oxygen demand and bilateral agreements penetrate on high-resolution computed tomography (HRCT) (for example earth exposure).

10 .While AE-IPF is becoming more well acknowledged as a serious occurrence with such extremely high death rate, there remains a scarcity of medical evidence on AE-ILD in non-IPF ILD. The goal of these study would be to offer a concise overview of AE-definition, ILD's disease manifestations, diagnostics, diagnosis, and therapy. By addition, this analysis would

provide an information on recent advancements in the area of AE-ILD, both in IPF and non-IPF ILD.

6.4 Connective tissues disease (CTD) associated pneumonias

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes chronic coronavirus infection 2019 (COVID-19), which presents in a number of ways, from symptomatic sickness to pneumonia and pulmonary disease. COVID-19 problems tend to also be increased by older years with associated heart problems. Due to its reduced respiratory reserves, individuals having collagenous illness interstitial lung disease (CTD-ILD) might just be a susceptible patient group for COVID-19[49]. There have been no longitudinal studies on the effects of SARS-CoV-2 infection in patients with CTD-ILD that we were aware of. They describe about this all documented instances involving COVID-19 in individuals with CTD-ILD seen at the University of California Los Angeles (UCLA) during January and August 2020.

EL, a 55-year-old Latino woman with hypertension and increasing systemic sclerosis–related (SSc) ILD, has been taking 1 g of mycophenolate mofetil (MMF) each day for the last 5 years (Table 1). After already being exposed to her son-in-law, whom screened confirmed for SARS-CoV-2 by nasopharyngeal swabs in early April 2020, the person suffering high fever, fatigue, hoarseness, coughing, and breathlessness. She went on a self-quarantine, stopped using MMF, and was given supported healthcare[50]. These difficulties subsided over three weeks, while her constant supplementary oxygen needs of 3–5 L were not increased. She came back positive for SARS-CoV-2 Specific antibodies on April 24. A pulmonary high computed tomography (HRCT) scan revealed mild to severe ILD that was otherwise unaltered, with no indications of grounded glass porosity or restructurings. MMF was restarted, and the individual has no COVID-19-related complications in the three months since her sickness.

Table 1: Characteristics of CTD-ILD patients before infection with COVID 19

	Case 1(EL) SSc [ILD]	**Case 2(RD) SSc [ILD]**	**Case 3(SP) RA [ILD]**	**Case 4(MF) SSc [ILD]**
Race	Latina	Latina	White	White
Sex	Female	Female	Female	Female
Age	56	67	70	57
Radiography ILD pattern	UIP	NSIP	UIP	UIP
ILD duration	6	8	5	13
FVC% Predicted	53	66	149	73
TLC % Predicted	45	67	127	67
DLCO % Predicted	13	54	75	44
Treatment duration immunomodulatory	4	2	4	5
Immunomodulatory Treatment and dose	MMF1g BID	MPA 759mg BID	AZA 49mg daily	MMF1g BID

VII. DRUG INDUCE ACUTE LUNG INJURY

Pulmonary edema as well as acute activation define acute lung injury/acute respiratory distress syndrome (ALI/ARDS). ALI/ARDS had been induced using lipo poly saccharide (LPS), the key component of Negative microorganisms. LPS-induced animal studies show how to investigate the causes of something like a variety of illnesses or might help with the development of new biomarker research strategies[51-52]. Evey design, though, does have its own set of advantages or disadvantages. The aim of this paper is to describe as well as assess the outcomes of experimental investigations in LPS-induced ALI/ARDS, as well as the molecular pathways and therapies that have been discovered. The benefits and drawbacks of such approaches in respiratory development, as well as fresh potential for future study, were also highlighted**.**

7.1 Diffuse alveolar damage (DAD)

Aims Diffuse alveolar damage (DAD) is a frequent condition with outpatient coronavirus disease 2019 (COVID-19) mortality, although newer studies also mention other unusual abnormalities, such as pathological changes. To better measure the relative effect that surgical assistance upon pulmonary histopathology, researchers compared pulmonary results of the investigation in COVID-19 hospitalized physicians against treatment, severe acute respiratory syndrome coronavirus 2 (SARSCoV2) positive persons who expired in the public[53]. In particular, they compare the pathological observations of COVID-19 participants with those of untreated normal controls to see if COVID-19 constitutes a distinct pharmacologic variation of DAD. Findings And Techniques Multiple respiratory

examiners, both of which were masked to the cohort of patients, examined respiratory segments of autopsy patients. COVID-19 develop patient, 4 patients with posthumous SARSCoV2 diagnosis whom expired inside the field, while SARSCoV2negative control groups made up the batches. Except for single SARSCoV2 confirmed person whom had been symptomatic or expired mostly in environment, DAD was found in every case[54]. Even though SARSCoV2 patients diagnosed had more focus point periventricular inflammatory conditions than control patients, there were no significantly different seen to compatriots mostly in appearance of hyphae cellular membrane, fibrin thrombus formation, airside institution, or "acute fibrinous as well as community organizing pneumonia like part presents fibronectin accumulation. COVID-19-related DAD did never really have fibrin vessel wall necrosis, bleeding, or capillaritis. Consequences DAD is the primarily dominated expression of chronic respiratory illness in COVID-19 individuals whom died both within the hospitalization and even out the neighborhood, indicating that perhaps these pathologic abnormalities were unrelated of hypoxemic respiratory support. They seem can be no distinguishing morphometric traits that can be used to clearly distinguish COVID-19-related with DAD caused through other factors.

Even as coronavirus ailment 2019 (COVID-19) emerging infectious diseases spreads all across globe, there would be a broad sense absence of unanimous agreement in the fast-expanding health literature about large extent to which acute respiratory distress syndrome (ARDS) caused by patients infected with acute respiratory syndrome[55]. coronavirus 2 (SARS-CoV-2) differs from ARDS caused through other causes. Although some individuals are regarded might be possess conventional ARDS symptoms, some have been considered be show unique symptoms or reflect an entirely novel implements the best. 1-4 Correspondingly, while pathophysiologic characterizations of respiratory adjustments in patient populations to potentially deadly COVID-19 are using the overriding diagnostic test of diffuse alveolar damage (DAD), some study highlights unique features such as notable fibrotic aviation secretions, variously showy lymphoid cells invades with characterizations of endotheliosis, as well as a variety of other vasculature such as fibrotic fibrosis of smaller boats, internal bleeding and vasculopathy, and small vessel.

VIII. PNEUMOCYTIS JIROVECII PNEUMONIA (PJP)

More than a million cases having was detected globally during fast expanding new coronavirus illness 2019 (COVID-19) epidemic; nevertheless, there are few instances of HIV and COVID-19 co - infection just at moment of this publishing. We present a case of (PJP) in an HIV-positive person. A 55-year-old man appeared with flu symptoms, coughing, and dyspnea over the previous seven days. Well-controlled HIV infection (diagnosed in 2006, current CD4+ cells count 422 cells/l (35.6 %), HIV-1 virus in the body 20 copies/ml), on emtricitabine /tenofovir disoproxil 200/245 mg as well as containing the name 1200 mg once day; moderate asthmatic.[56-57] He had no previous PJP experience, was a cigarette addict, shared a home alongside his companion, but had no recent tourism records or interaction other verified COVID-19 patients.

CT in something like the chest (Fig.2) revealed significant subpleural or para-mediastinal cysts alterations, as well as pleural effusion surface changes bilateral, particularly visible in the right lobe despite comparative preservation of the pulmonary bases, consistent with PJP. There were additional cases of intermittent inflammatory processes and parastatal emphysema.



Figure 2: CT in something like the chest revealed significant subpleural or para-mediastinal cysts alterations

Combinatorial PCR really does have been used the screen the chronic lung tissue phlegm with respiratory illnesses, although P. jirovecii DNA was found. Genuine PCR (RT-PCR) of a first combination nose or throat sample did not identify SARS-CoV-2 RNA (day 2). Additional pulmonary infections were just not found throughout the examination. Intravenous cotrimoxazole (120 mg/kg/24 h) or oral prednisone 40 mg twice day were used to start therapy[58]. Three days into therapy, he began to worsen that needed critical care. Using RT-PCR, SARS-CoV-2 were found in a repeated mouth sample (day 7).

Using increased oxygen, he was able to improve without the need for catheterization or

breathing. He was released since day 14 after completing 21 days of oral therapy and long-term PJP prophylaxis.

They provide the very first instance of P. jirovecii and SARS-CoV-2 identification in a person with HIV who was in good health. Just at time of this writing, just one additional HIV/COVID-19 coinfection case was reported[59-60], with limited details about the individuals personal Hiv testing.

1) As well as a European regional database of HIV/COVID-19 cases is now under progress.

2) They propose that epidemiologic information involving HIV/COVID-19 patients to also be gathered and published to investigate the link among COVID-19, HIV, or antimicrobial medication.RT-PCR using throat samples had been shown to have a selectivity of 95% in detecting SARS-CoV-2 RNA.

3) Historical investigations compared RT-PCR with integrated detailed clinical parameters to identify COVID-19 in an endemic scenario reported reduced RT-PCR responses of 70–80%.

4) The period from illness start is linked to lower diagnostic accuracy, which decrease form 100% in terms to 40% if administered after day 5 of complaints.

5) Its existence of SARS-CoV-2 was verified by retroactive analysis of such a participant's forced sputum, which was obtained around 26 hours after the negative throat swabs. With despite context a inconclusive nasopharyngeal specimens, generated phlegm specimen as from respiratory system might improve confirmation.

6) The Check to make diagnostic was based on the detection of P. jirovecii DNA in generated phlegm as well as an immediate bad SARS-CoV-2 result in the context of PJP-like characteristics. The relevance of P. jirovecii DNA identified by PCR.

7) However it might indicate colonisation of the circulatory tract. In this circumstance, fluorescence photography just wasn't accessible. In physically immune - competent people, the frequency of identifiable P. jirovecii DNA had reported estimated to vary between 0% and 20%.

8) Regarding physically However, immunoblotting imaging technology disclosed two very different tumor but instead trophozoite formation seductive of vigorously mimicking P. jirovecii through 100% of respiratory post mortem specimens from immunosuppressed grownups of perceptible P. jirovecii DNA

9) Implying that gentle PJP disease might well be prevalent even in immune - compromised adult women to discernible P. jirovecii DNA.COVID-19 or PJP have comparable disease manifestations such as persistent cough, workout dehydration, as well as a seemingly normal chest palpating.

10) Surface appearance combined interstitial septum thickness would be a common lung CT result for both diseases.

11) Inside the pandemic set - up, overlooked COVID-19 diagnostic tests can lead to bad decisions for contact traceability and protection of onward shipment. In serious PJP, elevated cortisone treatment is required.

12) However there is no indication for systemic corticosteroids throughout COVID-19, as well as observation - based findings indicates increased mortality and supplementary prevention of infection in whooping cough, as well as impeded clearing of the strongly linked SARS-CoV and MERS-CoV viral diseases.

13) Finally, they provide the very first example of a person living with Human immunodeficiency virus whose been confirmed with COVID-19 and PJP and managed both. Owing of overlap clinicopathologic symptoms but also limits that existing diagnostic, diagnosing either illness in the context including both viruses was difficult, having healthcare - associated concerns inside the present COVID-19 epidemic.

IX. PULMONARY EDEMA

COVID-19 is a serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related viral illness with a worldwide spread. By March 31st, 2021, there would have also seen a cumulative of 128.54 million instances with serious Coronavirus Sickness (COVID-19) identified worldwide, with 2.81 million individuals dying in a result of the disorder (WHO, 2021). While several existing medications have been adapted or authorised in managing inpatients, no particular treatment has been produced to combat COVID-19[61-62]. Many firms have already released COVID-19 vaccinations that have been licenced for usage. Another are anticipated to be authorised shortly. Unfortunately, it is still uncertain how immunizations would be carried out or whether quickly they may be completed. Meanwhile, researchers desperately want a significant decrease in COVID-19 mortality.

Pulmonary edoema occurs when there is an imbalance among the creation or reflux of lung tissue fluid, resulting in excessive muscle fluid intake by lung lymph or vascular collapse. Fluid enters or collects in the interstitial fluid of the lungs, eventually reaching the alveolars through lung capillaries, causing significant respiratory ventilating or gaseous exchanges problems.[63-64] Lung ultrasonography as well as a computed tomography (CT) scan are used to identify respiratory failure in COVID-19 patients. This illness manifests like a gradually progressing pneumonia with subtle early-onset intermittent pulmonary congestion that progresses to acute exacerbation with pulmonary edoema inside the later phases . These disorders are now the most common side effects of lung viral disease. SARS-CoV-2 infects mammalian tissues through attaching to the angiotensin-converting enzyme-2 (ACE-2) receptors or other membranes ectopeptidases,

according to research[65]. Whenever the virus is present, both viruses or viral-mediated protein interactions cause a lung inflammation maelstrom, which results to increased capillary porosity in the lungs with pulmonary edoema. Disruption to alveolar fluid clearance (AFC) is considered to have a central part for the growth of pulmonary edoema. This sudden aggravation of pulmonary edoema among COVID-19 individuals could be due to a mismatch of liquid metabolic, pulmonary fluid clearance (PFC), or rich-protein liquid entry[66]. The molecular underpinnings of PFC are described herein, therefore researchers argue that proteins involved with this activity could be underestimated but intriguing candidates for lowering pulmonary edoema in acute COVID-19 individuals. Ion channels (Na channel, K channel, or TRPV4), aquaporins (AQP), renin-angiotensin system (RAS) enzymes, or bradykinin/hyaluronic acid-related enzymes are among the proteins that are involved involved. At least a few of these enzymes have previously been targeted by medications, which might be reused to treat the respiratory failure found in SARS-COV-2 illnesses[67]. TCMs, which are currently extensively used in China, might well be useful in treating COVID-19 individuals with pulmonary congestion.

Numerous organic substances had also been proven to have beneficial impacts on the pulmonary edema-related objectives discussed throughout this research. Several clinical aspects of COVID-19, and also present and possible novel therapies focused on the decrease of pulmonary edoema by different techniques, such as pharmaceuticals, TCMs, and organic chemicals, are discussed in this study. Researchers believe that treating COVID-19 individuals with serious infections will result inside a decreased fatality rate.

9.1 Conventional Treatment of Pulmonary Edema in COVID-19 Patients

Several medical studies for coronavirus therapy are now underway, involving novel medicines or medication conversion or placement. Among individuals having serious infections, innate immunity drugs, supporting therapy, or antiviral medications have been investigated as COVID-19 therapies. Immune-modulatory agents for COVID-19 includes tocilizumab, recombinant immunoglobulin, or subacute plasma. Tocilizumab, an IL6 monoclonal antibody, was intended to function by interjecting this same inflammation storm which occurs after infectious disease, but just a recent medical study published England Journal of Medicine found it was insufficient to protect cannulation or death in gentle hospitalised COVID-19 patient populations. Although convalescent serum was first proven to be useful for COVID-19 individuals with symptomatic illness in terms of stabilising the immune response, a second randomised control experiment failed to demonstrate substantial improvements within 28 days.

Pulmonary or cardiac assistance are two types of COVID-19 supporting treatment. As pulmonary assistance, sick people receive a high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), mechanical ventilation, as well as ECMO, an osmotic fluid to maintain body water equilibration, as well as anticoagulants to prevent blood clotting to aid in providing greater. For COVID-19 sufferers, several supportive measures have been demonstrated to be effective as adjunctive treatment[68]. Re - purposed medications which had been shown to possess antiviral activity against different viruses have been tested. Unfortunately, the medications' effectiveness or safety in COVID-19 individuals remain unknown. Just remdesivir has been authorised either by FDA for compassionate use and in COVID-19 individuals who are severely sick. Several antiviral medications, like arbidol, chloroquine phosphate, or ritonavir, failed to show effectiveness in COVID-19 individuals in randomised, placebo-controlled studies. Notwithstanding, it appears fair should begin antiviral medication as soon as feasible in individuals having significant hazard variables, rather than waiting for the condition to become serious.

Additional therapeutic strategies, such as organ assistance, glucocorticoid therapy, and nutritional education, have been used in COVID-19 clinical studies with little information of their effectiveness. Furthermore, among all of the current therapies listed above, aberrant body's immune metabolism or respiratory failure, that is a major factor endangering sufferers' lives, has received relatively less consideration.

9.2. Pulmonary lymphangitis carcinomatosa

PLC, or respiratory lymphangitis concepts related, is a life-threatening condition in people with cancer. Delays for identification are frequently caused by deceptive or vague signs. Aim. This goal of this study was to look at a demographics, medical symptoms, or outcomes for individuals having PLC who had been described by the research. That work is the first comprehensive investigation of PLC that we are aware of. Ingredients or procedures. Researchers used the terms lungs, respiratory, lymphangitic, carcinoma, and concepts related and scan the database including publications released between 1970, and 2018. Due to the rarity with lung lymphangitis carcinomatosis, all data was gathered from case case studies studies, which included a method for identifying individual-level patient information. Outcomes. The total of 108 publications (139 patient's individual cases) were included into the final analysis. Overall average age at which PLC occurs is 49.21 years. There really is no variation among males or women with terms of frequency. Chest (17.3%), pulmonary (10.8%), as well as stomach malignancies were most prevalent underlying primary tumours that interact with PLC (10.8 %). A most prevalent symptoms are dyspnea or dried coughing, that are recorded by 59.0 % with 33.8 % of patients, correspondingly[69]. PLC occurred in half with an individuals within 10 months of their initial cancer

diagnosis. This diagnostic acute pulmonary lymphangitis carcinomatosis was linked with such a bad diagnosis: almost 50% the individuals died between two months of their initial respiratory problems or 3 weeks of hospitalisation. By terms of survival rates, researchers found that individuals documented during 2000, - 2018 had superior outcomes than those reported during 1970 to 1999.

Lymphangitic carcinomatosis is often observed primarily a result of adenocarcinomas like:

- breast cancer: most common
- lung cancer (adenocarcinoma in situ)
- colon cancer
- stomach cancer
- prostate cancer
- cervical cancer
- thyroid cancer

It's also observed in a variety of different basic tumours, such as laryngeal cancer, malignancy, and etc. Again for prevalent causes of lymphangitic carcinomatosis, an useful memorization is commonly utilised.

9.3 Treatment and prognosis

Depending histopathology of the initial tumour determines the treatments, however global chemotherapy is usually used.

Individuals with lymphangitic carcinomatosis have relatively terrible outlook, with over 50% dying to their condition inside a year after discovery. Long-term life does occur on occasions.

X. ELECTRONIC – CIGARETTE OR VAPING PRODUCT USE – ASSOCIATED LUNG INJURY (EVAL-I)

During 2019, the Centres for Disease Control as well as Prevention discovered an epidemic of a lung ailment among people who had previously vaped. This condition was assigned the term EVALI by their link to using digital cigarettes among younger individuals. EVALI appears medically like an acute viral disease, with respiratory problems reported by virtually most individuals. GI problems are recorded by 75% of patients, while subjective abnormalities are recorded by 85% of patient populations. EVALI is an exclusionary diagnosis[70]. While majority of individuals recover with supporting therapy, however a tiny number of individuals perish to the condition. Patients had unilateral or symmetrical diffused foggy GGOs with pleural effusion preservation but also no zonal preponderance on elevated CT. There could also be superior pulmonary zone–dominant central vein nodules. There's really indication of organisation later inside the illness phase, including architecture deformation with fibro symptoms.

The acronym EVALI refers for e-cigarette or vaping-related lung damage. Initially, it was called as VAPI (vaping associated pulmonary illness). This current name was chosen in reaction to an increasing number of serious respiratory disease instances linked to the use of e-cigarettes or vaping devices, one of which was discovered in 2019. Because researchers are continuously discovering about with this condition, modifications to a nomenclature might be introduced in the future. Vitamin E acetate (an addition in certain THC-containing e-cigarettes) is the predominant, although not exclusive, source of EVALI, according to healthcare experts. The CDC researchers assessed bronchoalveolar lavage (BAL) fluid from EVALI sufferers from Sixteen regions to BAL fluid from healthy persons. Vitamin E acetate is discovered in BAL fluid from 48 of 51 EVALI sufferers, but just not in either of the BAL liquids from healthy individuals, reported with these researchers[71-72]. Vitamin E acetate is similarly detected the item specimens analysed mostly by FDA or provincial labs.

Several additional compounds or chemical origins in vape materials are being investigated as probable culprits, including additional the e - liquids. The CDC is still looking into it, as were pulmonary health experts across the nation. During the initial coronavirus illness 2019 (COVID-19) outbreak around Apr 2020, this same California Department of Public Health recorded 8 patients hospitalised suffering e-cigarette, and vaping, device use–associated pulmonary injury (EVALI) (CDPH). Patients ages ranging from 14 to 50 years old (median = 17); seven are under the age of 21. All of the hospitalization took place during Apr 2020, a minimum of four days (scope: four to thirteen days) following the beginning of symptoms. 2 patients needed ventilators and were transferred to an acute care setting[73-74]. There at period of hospitalisation, most individuals had nucleic acid screening with SARS-CoV-2, the infection induces COVID-19; both tests came back negative. Lower respiratory specimens were tested from intubated and endotracheal patients, while 7 individuals are examined twice or more. Individuals satisfied the California or CDC EVALI diagnostic criteria, which included negative pulmonary virus tests with EVALI-like breast radiography features.

There at period of ospitalization, most individuals had nucleic acid screening with SARS-CoV-2, the infection induces COVID-19; both tests came back negative. Lower respiratory specimens were tested from endotracheal or endotracheal individuals, while 7 individuals are examined twice or more. Individuals satisfied the California or CDC EVALI diagnostic criteria, which included negative pulmonary virus tests with EVALI-like breast radiography features[75]. 2 patients said they got their vape items from acquaintances; 6 patients said they weren't questioned or didn't say where they got their vapes. Anyone over the age of 21 may consume recreational marijuana in

California. Individuals under the age of 21 that acknowledged using THC medicines may having obtained them from unregulated, unofficial methods.

XI. CONCLUSION

Inside a suitable medical situation, chest-CT provides a reliable screening approach which may detect COVID-19 infections. Although, object detection characteristics of COVID-19 pneumonia, that have been greatest commonly characterised by bilateral GGO inside a blotchy as well as decrease occipital pervasive dispersion, are non-specific as well as could indeed be seen in a variety of respiratory illnesses, contagious as well as non-infectious, and must everytime be regarded in the diagnostic process, particularly once COVID-19 preponderance inside the inhabitants is cheap. Detection of PLC must be evaluated in this same context of increasing discomfort, coughing, or abnormalities that are similar to those seen with pulmonary infections. Lung lymphangitis carcinomatosis can arise anywhere at ages it is the initial sign of a secondary hidden tumour. A most prevalent cancer that coexists with PLC is adenocarcinoma, which cancer - induced lungs, breast, or stomach malignancies. Owing to its overlapping with such a variety other distinct illness, most usual lung CT scanning findings in coronavirus illness 2019, (COVID-19) pneumonia possess a poor sensitivity. Using scanning instances, the analysis has concentrated on illustrating such discrepancies. It is indeed worth noting that when COVID-19 is prevalent, especially uncommon radiological characteristics are much more probable to be COVID-19. However, a conclusive diagnostic could be determined solely on the basis of Computed tomography characteristics, combining diverse medical results may greatly increase diagnostic reliability.

REFERENCE

[1] Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: Glossary of terms for thoracic imaging. Vol. 246, Radiology. Radiology; 2008. p. 697–722 -

[2] Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. Am J Roentgenol. 2020;215(2):338–343. -

[3] Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, Pan I, Shi LB, Wang DC, Mei J, Jiang XL, Zeng QH, Egglin TK, Hu PF, Agarwal S, Xie FF, Li S, Healey T, Atalay MK, Liao WH. Performance of radiologists in differentiating COVID-19 from non-COVID-19 viral pneumonia at chest CT. Radiology. 2020;296(2):E46–E54.

[4] Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest⁣ CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. J Thorac Imaging. 2020;35(4)

[5] Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, Schneider F, Labani A, Bilbault P, Molière S, Leyendecker P, Roy C, Ohana M. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels. Radiology. 2020;296(3):E189–E191.

[6] Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM. Chest CT Imaging Signature of Coronavirus Disease 2019 Infection: In Pursuit of the Scientific Evidence. Chest. 2020;

[7] Vilar J, Domingo ML, Soto C, Cogollos J. Radiology of bacterial pneumonia. Eur J Radiol. 2004;51(2):102–113. -

[8] Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention. Vol. 163, American Journal of Respiratory and Critical Care Medicine. American Lung Association; 2001. p. 1730–54 -

[9] Wagner AL, Szabunio M, Hazlett KS, Wagner SG. Radiologic manifestations of round pneumonia in adults. Am J Roentgenol. 1998;170(3):723–726. -

[10] Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, Saikku P. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56(4):296–301.

[11] Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344(9):665–671. -

[12] Höffken G, Niederman MS. Nosocomial pneumonia: The importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Vol. 122, Chest. American College of Chest Physicians; 2002. p. 2183–96 -

[13] Chastre J, Fagon JY. Ventilator-associated pneumonia. Vol. 165, American Journal of Respiratory and Critical Care Medicine. American Thoracic Society; 2002. p. 867–903 -

[14] Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CT features of viral pneumonia. Vol. 38, Radiographics. Radiological Society of North America Inc.; 2018. p. 719–39 -

[15] Cereser L, Dallorto A, Candoni A, Volpetti S, Righi E, Zuiani C, et al. Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers. Vol. 116, European Journal of Radiology. Elsevier Ireland Ltd; 2019. p. 116–27 -

[16] Yin Z, Kang Z, Yang D, Ding S, Luo H, Xiao E. A comparison of clinical and chest CT findings in patients with influenza a (H1N1) virus infection and coronavirus

disease (COVID-19) Am J Roentgenol. 2020;215(5):1–7. -
[17] Liu M, Zeng W, Wen Y, Zheng Y, Lv F, Xiao K. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020;30(10):5463–5469.
[18] Li X, Fang X, Bian Y, Lu J. Comparison of chest CT findings between COVID-19 pneumonia and other types of viral pneumonia: a two-center retrospective study. Eur Radiol. 2020;30(10):5470–5478.
[19] Roshkovan L, Chatterjee N, Galperin-Aizenberg M, Gupta N, Shah R, Barbosa EM, et al. The Role of Imaging in the Management of Suspected or Known COVID-19 Pneumonia: A Multidisciplinary Perspective. Ann Am Thorac Soc. 2020 Oct 6; -
[20] Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: High-resolution CT findings in patients with and without HIV infection. Vol. 198, American Journal of Roentgenology. AJR Am J Roentgenol; 2012 -
[21] Roux A, Gonzalez F, Roux M, Mehrad M, Menotti J, Zahar JR, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Vol. 44, Medecine et Maladies Infectieuses. Elsevier Masson SAS; 2014. p. 185–98 -
[22] Hardak E, Brook O, Yigla M. Radiological features of pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS. Lung. 2010;188(2):159–163. -
[23] Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, Inoue Y, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69.
[24] Churg A, Muller NL, Flint J, Wright JL. Chronic hypersensitivity pneumonitis. Am J Surg Pathol. 2006;30(2):201–208. -
[25] Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, Kazerooni EA, Myers JL, Lagstein A, Konopka KE, Belloli EA, Sheth JS, White ES, Holtze C, Martinez FJ, Flaherty KR. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest. 2019;155(4):699–711.
[26] Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, Woodruff PG, Jones KD, Collard HR, King TE, Jr, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013;144(2):586–592.
[27] MB B, TJ F, JR G, B G, WD T. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med. 2002;126(9) -
[28] Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748.
[29] Gomes R, Padrão E, Dabó H, Soares Pires F, Mota P, Melo N, et al. Acute fibrinous and organizing pneumonia: A report of 13 cases in a tertiary university hospital. Med (United States). 2016 Jul 1;95(27)
[30] Kim JY, Doo KW, Jang HJ. Acute fibrinous and organizing pneumonia: imaging features, pathologic correlation, and brief literature review☆. Radiol Case Reports. 2018;13(4):867–870.
[31] Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol. 2015;84(3):542–546. -
[32] Bernheim A, McLoud T. A review of clinical and imaging findings in eosinophilic lung diseases. Vol. 208, American Journal of Roentgenology. American Roentgen Ray Society; 2017. p. 1002–10 -
[33] Allen JN, Pacht ER, Gadek JE, Davis WB. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med. 1989;321(9):569–574. -
[34] De Giacomi F, Decker PA, Vassallo R, Ryu JH. Acute eosinophilic pneumonia: correlation of clinical characteristics with underlying cause. Chest. 2017;152(2):379–385. -
[35] Komiya K, Teramoto S, Kawashima M, Kurosaki Y, Shoji S, Hebisawa A. A case of acute eosinophilic pneumonia following short-term passive smoking:an evidence of very high level of urinary cotinine. Allergol Int. 2010;59(4):421–423. -
[36] Buchheit J, Eid N, Rodgers G, Feger T, Yakoub O. Acute eosinophilic pneumonia with respiratory failure: A new syndrome? In: American Review of Respiratory Disease. Am Rev Respir Dis; 1992. p. 716–8 -
[37] Allen J. Acute eosinophilic pneumonia. Vol. 27, Seminars in Respiratory and Critical Care Medicine. Semin Respir Crit Care Med; 2006. p. 142–7 -
[38] Rhee CK, Min KH, Yim NY, Lee JE, Lee NR, Chung MP, Jeon K. Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J. 2013;41(2):402–409. -
[39] De Giacomi F, Vassallo R, Yi ES, Ryu JH. Acute eosinophilic pneumonia. Am J Respir Crit Care Med. 2018;197(6):728–736. -
[40] Suzuki Y, Suda T. Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management. Vol. 68, Allergology International. Japanese Society of Allergology; 2019. p. 413–9 -

[41] Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Vol. 137, Chest. American College of Chest Physicians; 2010. p. 1164–71 -
[42] Lichtenberger JP, Digumarthy SR, Abbott GF, Shepard JAO, Sharma A. Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol. 2014;43(3):128–139. -
[43] Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997;76(3):192–202. -
[44] Gluecker T, Capasso P, Schnyder P, Gudinchet F, Schaller MD, Revelly JP, Chiolero R, Vock P, Wicky S. Clinical and radiologic features of pulmonary edema. Radiographics. 1999;19(6):1507–1531. -
[45] Hewitt MG, Miller WT, Reilly TJ, Simpson S. The relative frequencies of causes of widespread ground-glass opacity: a retrospective cohort. Eur J Radiol. 2014;83(10):1970–1976. -
[46] Nowers K, Rasband JD, Berges G, Gosselin M. Approach to ground-glass opacification of the lung. Semin Ultrasound CT MRI. 2002;23(4):302–323. -
[47] Klimek M. Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970–2018. Vol. 131, Postgraduate Medicine. Taylor and Francis Inc.; 2019. p. 309–18 -
[48] Bruce DM, Heys SDEO. Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb. 1996;41(1):7–13. -
[49] Digumarthy SR, Fischman AJ, Kwek BH, Aquino SL. Fluorodeoxyglucose positron emission tomography pattern of pulmonary lymphangitic carcinomatosis. J Comput Assist Tomogr. 2005;29(3):346–349. -
[50] Moubax K, Wuyts W, Vandecaveye V, Prenen H. Pulmonary lymphangitic carcinomatosis as a primary manifestation of gastric carcinoma in a young adult: A case report and review of the literature. Vol. 5, BMC Research Notes. BMC Res Notes; 2012
[51] Brander L, Reil A, Bux J, Taleghani BM, Regli B, Takala J. Severe transfusion-related acute lung injury. Anesth Analg. 2005;101(2):499–501. -
[52] Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg. 2009;108(3):770–776. -
[53] Antoniou KM, Wells AU. Acute exacerbations of idiopathic pulmonary fibrosis. Vol. 86, Respiration. Respiration; 2013. p. 265–74 -
[54] Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Vol. 27, European Respiratory Review. European Respiratory Society; 2018 -
[55] Park IN, Kim DS, Shim TS, Lim CM, Do LS, Koh Y, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214–220.
[56] Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143–150. -
[57] Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. Vol. 58, Histopathology. Histopathology; 2011. p. 525–30 -
[58] Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Vol. 176, American Journal of Respiratory and Critical Care Medicine. Am J Respir Crit Care Med; 2007. p. 636–43
[59] Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(4):372–378. -
[60] Fujimoto K, Taniguchi H, Johkoh T, Kondoh Y, Ichikado K, Sumikawa H, Ogura T, Kataoka K, Endo T, Kawaguchi A, Müller NL Acute exacerbation of idiopathic pulmonary fibrosis: High-resolution CT scores predict mortality. Vol. 22, European Radiology. Eur Radiol; 2012. p. 83–92 -
[61] Kligerman S, Raptis C, Larsen B, Henry TS, Caporale A, Tazelaar H, et al. Radiologic, pathologic, clinical, and physiologic findings of electronic cigarette or vaping product use-associated lung injury (EVALI): Evolving knowledge and remaining questions. Vol. 294, Radiology. Radiological Society of North America Inc.; 2020. p. 491–505 -
[62] Henry TS, Kligerman SJ, Raptis CA, Mann H, Sechrist JW, Kanne JP. Imaging findings of vaping-associated lung injury. Am J Roentgenol. 2020;214(3):498–505. -
[63] O'Laughlin K, Pomeroy M, Atti SK, Freed J, Johnson J, McLanahan E, Varela K, Layden J, Meiman J, Roth NM, Browning D, Delaney A, Olson S, Hodges DF, Smalley R, Council of State and Territorial Epidemiologists Vaping-Associated Pulmonary Injury (VAPI) Epidemiology Task Force Update: interim guidance for health care providers evaluating and caring for patients with suspected E-cigarette, or vaping, product use associated lung injury — United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68(41):919–927.
[64] MacMurdo M, Lin C, Saeedan M Bin, Doxtader EE, Mukhopadhyay S, Arrossi V, et al. e-Cigarette or Vaping Product Use-Associated Lung Injury: Clinical, Radiologic, and Pathologic Findings of 15 Cases. In: Chest. Elsevier Inc; 2020. p. e181–7 -
[65] Ellis SJ, Cleverley JR, Muller NL. Drug-induced lung disease: High-resolution CT findings. In: American Journal of Roentgenology. American Roentgen Ray Society; 2000. p. 1019–24 -
[66] Sakai F, Johkoh T, Kusumoto M, Arakawa H, Takahashi M. Drug-induced interstitial lung disease in molecular targeted therapies: High-resolution CT findings. Vol. 17, International Journal of Clinical Oncology. Int J Clin Oncol; 2012. p. 542–50.

[67] Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, Ling Y, Jiang Y, Shi Y. Emerging 2019 novel coronavirus (2019-NCoV) pneumonia. Radiology. 2020;295(1):210–217.
[68] WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2020 Oct 11]. Available from: https://covid19.who.int/info
[69] Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Vol. 296, Radiology. Radiological Society of North America Inc.; 2020. p. E115–7
[70] Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Vol. 295, Radiology. Radiological Society of North America Inc.; 2020. p. 22–3.
[71] Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: relationship to negative RT-PCR testing. Radiology. 2020;296(2):E41–E45.
[72] Kim H, Hong H, Ho YS. Diagnostic performance of ct and reverse transcriptase polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020;296(3):E145–E155.
[73] Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32–E40.
[74] Litmanovich DE, Chung M, R. R. Kirkbride, Kicska G, P. J. Kanne. Review of Chest Radiograph Findings of COVID-19 Pneumonia and Suggested Reporting Language. J Thorac Imaging. 2020; -
[75] Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner society. Chest. 2020;158(1):106–116.